Michael Mauer.

Michael Mauer, M.D., Bernard Zinman, M http://silagracipla.net/contact .D., Robert Gardiner, M.D., Samy Suissa, Ph.D., Alan Sinaiko, M.D., Trudy Strand, R.N., Keith Drummond, M.D., Sandra Donnelly, M.D., Paul Goodyer, M.D., Marie Claire Gubler, M.D., and Ronald Klein, M.D., M.P.H.: Retinal and Renal Effects of Enalapril and Losartan in Type 1 Diabetes Diabetic nephropathy, responsible for more than 45 percent of cases of end-stage renal disease in the usa,1 could be advanced once albuminuria becomes detectable structurally.7 Although the reduced amount of proteinuria in patients with diabetes has been associated with a reduction in the price of decline in GFR in small studies,8 this association has not been tested; furthermore, proteinuria reduction isn’t a generally accepted surrogate for hard clinical end points such as end-stage renal disease.9 Intensive multifactorial intervention in patients with type 2 diabetes with microalbuminuria nearly halved the progression of proteinuria but did not alter the rate of GFR decline.

Gange, Ph.D., Alison G. Abraham, Ph.D., Barry Merriman, M.A., Michael S. Saag, M.D., Amy C. Justice, M.D., Ph.D., Robert S. Hogg, Ph.D., Steven G. Deeks, M.D., Joseph J. Eron, M.D., John T. Brooks, M.D., Sean B. Rourke, Ph.D., M. John Gill, M.B., Ch.B., Ronald J. Bosch, Ph.D., Jeffrey N. Martin, M.D., M.P.H., Marina B. Klein, M.D., Lisa P. Jacobson, Sc.D., Benigno Rodriguez, M.D., Timothy R. Sterling, M.D., Gregory D. Kirk, M.D., Ph.D., Sonia Napravnik, Ph.D., Anita R. Rachlis, M.D., Liviana M. Calzavara, Ph.D., Michael A. Horberg, M.D., Michael J. Silverberg, Ph.D., Kelly A. Gebo, M.D., M.P.H., James J.